Phase i trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1019-1029

  Lam, Elaine T ^a   Au, Jessie L S ^a   Otterson, Gregory A ^a   Guillaume Wientjes, M ^a   Chen, Ling ^a   Shen, Tong ^a   Wei, Yong ^a   Li, Xiaobai ^a   Bekaii Saab, Tanios ^a   Murgo, Anthony J ^b   Jensen, Rhonda R ^a   Grever, Michael ^a   Villalona Calero, Miguel A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemosensitizer; Docetaxel; Gemcitabine; Modulator; Non small cell lung cancer; Suramin

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; SURAMIN; TEMOZOLOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALOSIS; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; RADIOTHERAPY, ADJUVANT; SURAMIN; TAXOIDS; TREATMENT OUTCOME;

EID: 78149409696     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1252-x     Document Type: Article

References (44)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. HK Weir MJ Thun BF Hankey, et al. 2003 Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control J Natl Cancer Inst 95 1276 1299 12953083
3. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer N Engl J Med 355 2542 2550 1:CAS:528:DC%2BD28XhtlWqsbzI 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
4. K Kelly J Crowley PA Bunn Jr, et al. 2001 Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial J Clin Oncol 19 3210 3218 1:CAS:528:DC%2BD3MXltlShtb4%3D 11432888
5. JK Weick J Crowley RB Natale, et al. 1991 A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: a southwest oncology group study J Clin Oncol 9 1157 1162 1:STN:280:DyaK3M3lvFWltw%3D%3D 1646292
6. JH Schiller D Harrington CP Belani, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 92 98 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
7. F Cardenal MP Lopez-Cabrerizo A Anton, et al. 1999 Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer J Clin Oncol 17 12 18 1:CAS:528:DyaK1MXltVyksw%3D%3D 10458212
8. AB Sandler J Nemunaitis C Denham, et al. 2000 Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall cell lung cancer J Clin Oncol 18 122 130 1:CAS:528:DC%2BD3cXmtFSruw%3D%3D 10623702
9. L Crinò AM Mosconi G Scagliotti, et al. 1999 Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial J Clin Oncol 17 2081 2085 10561261
10. JW Van Putten P Baas H Codrington, et al. 2001 Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small cell lung cancer Lung Cancer 33 289 298 10.1016/S0169-5002(01)00188-X 11551424 (Pubitemid 32707909)
11. FV Fossella R DeVore RN Kerr, et al. 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2354 2362 1:CAS:528:DC%2BD3cXkvFWrsLg%3D 10856094
12. J Dancey FA Shepherd RJ Gralla YS Kim 2004 Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial Lung Cancer 43 183 194 10.1016/j.lungcan.2003.09.001 14739039 (Pubitemid 38114747)
13. FA Shepherd J Dancey R Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 1:CAS:528:DC%2BD3cXktVyjsLc%3D 10811675
14. F Hawking 1978 Suramin: with special reference to onchocerciasis Adv Pharmacol Chemother 15 289 322 1:CAS:528:DyaE1MXjtlKhtw%3D%3D 10.1016/S1054-3589(08)60486-X 358805
15. M Hosang 1985 Suramin binds to platelet-derived growth factor and inhibits its biological activity J Cell Biochem 29 265 273 1:CAS:528: DyaL28XivFCntw%3D%3D 10.1002/jcb.240290310 4077932 (Pubitemid 16213984)
16. JS Garrett SR Coughlin HL Niman, et al. 1984 Blockade of autocrine stimulation in simian sarcoma virus transformed cells reverses down-regulation of platelet-derived growth factor receptors Proc Natl Acad Sci USA 81 7466 7470 1:CAS:528:DyaL2MXhvVCitQ%3D%3D 10.1073/pnas.81.23.7466 6095298 (Pubitemid 15196203)
17. M Pollak M Richard 1990 Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells J Natl Cancer Inst 82 1349 1352 1:CAS:528:DyaK3cXmt1Chsr0%3D 10.1093/jnci/82.16.1349 2166171
18. CW Taylor R Lui P Fanta SE Salmon 1992 Effects of suramin on in vitro growth of fresh human tumors J Natl Cancer Inst 84 489 494 1:CAS:528: DyaK38XisVOku7g%3D 10.1093/jnci/84.7.489 1545438
19. GJ Rubio HM Pinedo J Virizuela, et al. 1995 Effects of suramin on human lung cancer cell lines Eur J Cancer 31A 244 251 1:CAS:528:DyaK2MXltleqsLw%3D 10.1016/0959-8049(94)00444-A 7718332
20. PJ Rosen EF Mendoza EM Landaw, et al. 1996 Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy J Clin Oncol 14 1626 1636 1:CAS:528:DyaK28XjtFKisbg%3D 8622081
21. EJ Small M Meyer ME Marshall, et al. 2000 Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 1440 1450 1:CAS:528:DC%2BD3cXivVeisrg%3D 10735891
22. MR Mirza E Jakobsen P Pfeiffer, et al. 1997 Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies Acta Oncol 36 171 174 1:STN:280:DyaK2s3osFWlsw%3D%3D 10.3109/02841869709109226 9140434
23. A Falcone E Pfanner C Cianci, et al. 1995 Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study Cancer 75 440 443 1:STN:280:DyaK2M7ht1agsw%3D%3D 10.1002/1097-0142(19950115)75:2<440::AID-CNCR2820750205>3.0.CO;2-3 7812913
24. R Dreicer DC Smith RD Williams WA See 1999 Phase II trial of suramin in patients with metastatic renal cell carcinoma Invest New Drugs 17 183 186 1:CAS:528:DC%2BD3cXkslCquw%3D%3D 10.1023/A:1006331518952 10638490
25. RV La Rocca J Meer RW Gilliatt, et al. 1990 Suramin-induced polyneuropathy Neurology 40 954 960 1:STN:280:DyaK3c3msFGgtg%3D%3D 2161094
26. K Kobayashi RE Weiss NJ Vogelzang, et al. 1996 Mineralocorticoid insufficiency due to suramin therapy Cancer 78 2411 2420 1:CAS:528: DyaK28XnsFSitbs%3D 10.1002/(SICI)1097-0142(19961201)78:11<2411::AID- CNCR20>3.0.CO;2-2 8941013 (Pubitemid 26392842)
27. E May B Allolio 1991 Fatal toxic epidermal necrolysis during suramin therapy Eur J Cancer 27 1338 1:STN:280:DyaK38%2FmvVKnsg%3D%3D 1842674
28. MK Horne III OJ Wilson M Cooper, et al. 1992 The effect of suramin on laboratory tests of coagulation Thromb Haemost 67 434 439 1631791
29. WD Figg MR Cooper A Thibault, et al. 1994 Acute renal toxicity associated with suramin in the treatment of prostate cancer Cancer 74 1612 1614 1:STN:280:DyaK2czktVGisA%3D%3D 10.1002/1097-0142(19940901)74:5<1612::AID- CNCR2820740519>3.0.CO;2-Q 8062193 (Pubitemid 24302983)
30. S Song MG Wientjes Y Gan JL Au 2000 Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs Proc Natl Acad Sci USA 97 8658 8663 1:CAS:528:DC%2BD3cXlt1GnsLg%3D 10.1073/pnas.140210697 10890892 (Pubitemid 30639729)
31. Y Zhang S Song F Yang JL Au MG Wientjes 2001 Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors J Pharmacol Exp Ther 299 426 433 1:CAS:528:DC%2BD3MXnvV2qsLY%3D 11602651 (Pubitemid 32979652)
32. S Song MG Wientjes C Walsh JL Au 2001 Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases Cancer Res 61 6145 6150 1:CAS:528:DC%2BD3MXmt12ktLc%3D 11507065 (Pubitemid 32762551)
33. Z Lu TS Wientjes JL Au 2005 Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors Pharm Res 22 1069 1078 1:CAS:528:DC%2BD2MXmt1ynurw%3D 10.1007/s11095-005-6038-1 16028007 (Pubitemid 41127064)
34. Y Gan MG Wientjes JL Au 2006 Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors Pharm Res 23 1324 1331 1:CAS:528:DC%2BD28XmtFCntrg%3D 10.1007/s11095-006-0136-6 16741658 (Pubitemid 43946154)
35. C Behrens HY Yin JJ Lee, et al. 2008 Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer Clin Cancer Res 14 6014 6022 1:CAS:528:DC%2BD1cXhtF2nurrO 10.1158/1078-0432.CCR-08-0167 18829480
36. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
37. MA Villalona-Calero MG Wientjes GA Otterson, et al. 2003 Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer Clin Cancer Res 9 3303 3311 1:CAS:528:DC%2BD3sXotFCksLk%3D 12960116
38. MA Villalona-Calero GA Otterson MG Wientjes, et al. 2008 Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small cell lung cancer: a phase II study Ann Oncol 19 1903 1909 1:STN:280:DC%2BD1cnosVKitg%3D%3D 10.1093/annonc/mdn412 18632723
39. D Chen SH Song MG Wientjes, et al. 2006 Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development Pharm Res 23 1265 1274 10.1007/s11095-006-0165-1 16715360 (Pubitemid 43946148)
40. Walsh CT, Wei Y, Wientjes MG, Au JL (2008). Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance. J Transl Med 6:4. Published online 2008 January 18. doi: 10.1186/1479-5876-6-4 (Pubitemid 351420118)
41. A Trotti R Byhardt J Stetz, et al. 2000 Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 13 47 1:STN:280:DC%2BD3c3itlCjsg%3D%3D 10758303
42. M Kassack P Nickel 1996 Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues J Chromatogr B Biomed Appl 686 275 284 1:CAS:528:DyaK2sXltVej 10.1016/S0378-4347(96)00214-9 8971610 (Pubitemid 26402967)
43. ®) Prescribing Information, Eli Lilly and Company, 1996 and 2007
44. ®) Prescribing Information, Sanofi-Aventis US LLC, 2008